123 related articles for article (PubMed ID: 20219328)
1. Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria.
Nicolosi D; Scalia M; Nicolosi VM; Pignatello R
Int J Antimicrob Agents; 2010 Jun; 35(6):553-8. PubMed ID: 20219328
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnology approaches for antibacterial drug delivery: Preparation and microbiological evaluation of fusogenic liposomes carrying fusidic acid.
Nicolosi D; Cupri S; Genovese C; Tempera G; Mattina R; Pignatello R
Int J Antimicrob Agents; 2015 Jun; 45(6):622-6. PubMed ID: 25816979
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species.
Farrell DJ; Robbins M; Rhys-Williams W; Love WG
Int J Antimicrob Agents; 2010 Jun; 35(6):531-6. PubMed ID: 20346634
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains.
Alipour M; Halwani M; Omri A; Suntres ZE
Int J Pharm; 2008 May; 355(1-2):293-8. PubMed ID: 18164881
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of liposome encapsulated cyclo(L-tyrosyl-L-prolyl).
Kilian G; Tshanga SS; Oidu B; Milne PJ
Pharmazie; 2011 Jun; 66(6):421-3. PubMed ID: 21699080
[TBL] [Abstract][Full Text] [Related]
6. Dual antibacterial mechanisms of nisin Z against Gram-positive and Gram-negative bacteria.
Kuwano K; Tanaka N; Shimizu T; Nagatoshi K; Nou S; Sonomoto K
Int J Antimicrob Agents; 2005 Nov; 26(5):396-402. PubMed ID: 16226432
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens.
Klietmann W; Focht J; Nösner K
Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332
[TBL] [Abstract][Full Text] [Related]
9. A peptide derived from human bactericidal/permeability-increasing protein (BPI) exerts bactericidal activity against Gram-negative bacterial isolates obtained from clinical cases of bovine mastitis.
Chockalingam A; McKinney CE; Rinaldi M; Zarlenga DS; Bannerman DD
Vet Microbiol; 2007 Nov; 125(1-2):80-90. PubMed ID: 17560054
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT
J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
[TBL] [Abstract][Full Text] [Related]
11. Pyrrolobenzodiazepine dimers: novel sequence-selective, DNA-interactive, cross-linking agents with activity against Gram-positive bacteria.
Hadjivassileva T; Thurston DE; Taylor PW
J Antimicrob Chemother; 2005 Sep; 56(3):513-8. PubMed ID: 16024592
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation of vancomycin and gentamicin within cationic liposomes for inhibition of growth of Staphylococcus epidermidis.
Sanderson NM; Jones MN
J Drug Target; 1996; 4(3):181-9. PubMed ID: 8959490
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
Garrison MW; Mutters R; Dowzicky MJ
Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
[TBL] [Abstract][Full Text] [Related]
15. In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay.
Pankey GA; Ashcraft DS
Diagn Microbiol Infect Dis; 2009 Jul; 64(3):300-4. PubMed ID: 19501791
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of aztreonam--a new monocyclic beta-lactam antibiotic.
Friis H
Dan Med Bull; 1985 Jun; 32(3):196-8. PubMed ID: 4040456
[TBL] [Abstract][Full Text] [Related]
17. Dual mechanism of bacterial lethality for a cationic sequence-random copolymer that mimics host-defense antimicrobial peptides.
Epand RF; Mowery BP; Lee SE; Stahl SS; Lehrer RI; Gellman SH; Epand RM
J Mol Biol; 2008 May; 379(1):38-50. PubMed ID: 18440552
[TBL] [Abstract][Full Text] [Related]
18. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of the combination trimethoprim plus sulfamethoxazole compared with that of other chemotherapeutic agents.
Focht J; Klietmann W; Nösner K
Arzneimittelforschung; 1988 Aug; 38(8):1085-8. PubMed ID: 3264166
[TBL] [Abstract][Full Text] [Related]
20. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
